Pan-pathway based interaction profiling of FDA-approved nucleoside and nucleobase analogs with enzymes of the human nucleotide metabolism

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Egeblad, Louise ^a   Welin, Martin ^b   Flodin, Susanne ^b   Gräslund, Susanne ^b   Wang, Liya ^a   Balzarini, Jan ^c   Eriksson, Staffan ^a   Nordlund, Pär ^b,d  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACICLOVIR; ADENOSINE TRIPHOSPHATE; CLADRIBINE; CLOFARABINE; CYTARABINE; DEOXYCYTIDINE KINASE; EMTRICITABINE; ENZYME; FLOXURIDINE; FLUOROURACIL; GANCICLOVIR; GEMCITABINE; GUANINE DEAMINASE; IDOXURIDINE; LAMIVUDINE; MERCAPTOPURINE; NUCLEIC ACID BASE; NUCLEOSIDE ANALOG; PENCICLOVIR; TELBIVUDINE; TIOGUANINE; TRIFLURIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE PHOSPHORYLASE; URIDINE PHOSPHORYLASE 1; VALACICLOVIR; VIDARABINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; DRUG INTERACTION; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME KINETICS; ENZYME STABILITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; FOOD AND DRUG ADMINISTRATION; NUCLEOTIDE METABOLISM; NUCLEOTIDE SEQUENCE;

DRUG DESIGN; ENZYME ASSAYS; ENZYMES; GUANINE DEAMINASE; HUMANS; KINETICS; METABOLIC NETWORKS AND PATHWAYS; NUCLEOSIDES; NUCLEOTIDES; RIBONUCLEOTIDE REDUCTASES; URIDINE PHOSPHORYLASE;

EID: 84861467901     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037724     Document Type: Article

References (43)

1. De Clercq E, (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33: 307-20.
2. De Clercq E, Field HJ, (2006) Antiviral prodrugs- the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 147: 1-11.
3. Galmarini CM, Mackey JR, Dumontet C, (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3: 415-24.
4. Friedman MA, Sadee W, (1978) The fluoropyrimidines: biochemical mechanisms and design of clinical trials. Cancer Chemother Pharmacol 1: 77-82.
5. Welin M, Nordlund P, (2010) Understanding specificity in metabolic pathways-structural biology of human nucleotide metabolism. Biochem Biophys Res Commun 396: 157-63.
6. Ericsson UB, Hallberg BM, Detitta GT, Dekker N, Nordlund P, (2006) Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal Biochem 357: 289-98.
7. Vedadi M, Niesen FH, Allali-Hassani A, Fedorov OY, Finerty PJ Jr, et al. (2006) Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci U S A 103: 15835-40.
8. Fedorov O, Marsden B, Pogacic V, Rellos P, Muller S, et al. (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A 104: 20523-8.
9. Allali-Hassani A, Pan PW, Dombrovski L, Najmanovich R, Tempel W, et al. (2007) Structural and chemical profiling of the human cytosolic sulfotransferases. PLoS Biol 5: e97.
10. Senisterra GA, Markin E, Yamazaki K, Hui R, Vedadi M, et al. (2006) Screening for ligands using a generic and high-throughput light-scattering-based assay. J Biomol Screen 11: 940-8.
11. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36: D901-6.
12. Wishart DS, Knox C, Guo, AC, Shrivastava S, Hassanali M, et al. (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34: D668-72.
13. Munir S, Saleem S, Idrees M, Tariq A, Butt S, et al. (2010) Hepatitis C treatment: current and future perspectives. Virol J 7: 296.
14. Yuen MF, Lai CL, (2011) Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol 26: 138-43.
15. Vedadi M, Arrowsmith CH, Allali-Hassani A, Senisterra G, Wasney GA, (2010) Biophysical characterization of recombinant proteins: a key to higher structural genomics success. J Struct Biol 172: 107-19.
16. Eriksson S, Munch-Petersen B, Johansson K, Eklund H, (2002) Structure and function of cellular deoxyribonucleoside kinases. Cell Mol Life Sci 59: 1327-46.
17. Peters GJ, (2006) Deoxynucleoside Analogs in Cancer Therapy. First edition, ed. Teicher BA, Humana Press Inc. Totowa, New Jersey.
18. Beausejour CM, Gagnon J, Primeau M, Momparler RL, (2002) Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. Biochem Biophys Res Commun 293: 1478-84.
19. Renck D, Ducati RG, Palma MS, Santos DS, Basso LA, (2010) The kinetic mechanism of human uridine phosphorylase 1: Towards the development of enzyme inhibitors for cancer chemotherapy. Arch Biochem Biophys 497: 35-42.
20. Cao D, Russell RL, Zhang D, Leffert JJ, Pizzorno G, (2002) Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 62: 2313-7.
21. Friedman MA, Sadee W, (1978) The fluoropyrimidines: biochemical mechanisms and design of clinical trials. Cancer Chemother Pharmacol 1: 77-82.
22. Pizzorno G, Cao D, Leffert JJ, Russell RL, Zhang D, et al. (2002) Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. Biochim Biophys Acta 1587: 133-44.
23. Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, et al. (1998) Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res 4: 1165-75.
24. Calabresi P, Falcone A, St Clair MH, Wiemann MC, Chu SH, et al. (1990) Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity. Blood 76: 2210-5.
25. Yuan G, Bin JC, McKay DJ, Snyder FF, (1999) Cloning and characterization of human guanine deaminase. Purification and partial amino acid sequence of the mouse protein. J Biol Chem 274: 8175-80.
26. Firestein BL, Firestein, BL, Brenman JE, Aoki C, Sanchez-Perez AM, et al. (1999) Cypin: a cytosolic regulator of PSD-95 postsynaptic targeting. Neuron 24: 659-72.
27. Kubo K, Honda H, Honda H, Sannomiya K, Aying Y, et al. (2006) Histochemical and immunohistochemical investigation of guanase and nedasin in human tissues. J Med Invest 53: 264-70.
28. Matsunaga H, Honda H, Kubo K, Sannomiya K, Cui X, et al. (2003) Clinical value of the determination of serum guanase activity in patients with chronic hepatitis type C. J Med Invest 50: 64-71.
29. Fernandez JR, Byrne B, Firestein BL, (2009) Phylogenetic analysis and molecular evolution of guanine deaminases: from guanine to dendrites. J Mol Evol 69: 227-35.
30. Bergstrom JD, Bieber AL, (1979) Characterization of purified guanine aminohydrolase. Arch Biochem Biophys 194: 107-16.
31. Rossi CA, Hakim G, Solaini G, (1978) Purification and properties of pig brain guanine deaminase. Biochim Biophys Acta 526: 235-46.
32. Fernandez JR, Sweet ES, Welsh WJ, Firestein BL, (2010) Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine. Bioorg Med Chem 18: 6748-55.
33. Reichard P, (2002) Ribonucleotide reductases: the evolution of allosteric regulation. Arch Biochem Biophys 397: 149-55.
34. Nordlund P, Reichard P, (2006) Ribonucleotide reductases. Annu Rev Biochem 75: 681-706.
35. Fairman JW, Wijerathna SR, Ahmad MF, Xu H, Nakano R, et al. (2011) Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization. Nat Struct Mol Biol 18: 316-22.
36. Usova EV, Eriksson S, (1997) The effects of high salt concentrations on the regulation of the substrate specificity of human recombinant deoxycytidine kinase. Eur J Biochem 248: 762-6.
37. Kabsch W, (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Cryst 26: 795-800.
38. Collaborative, (1994) The CCP4 suite: programs for protein crystallography, in Acta Crystallographica Section D p pp. 760-763.
39. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-32.
40. Murshudov GN, Vagin AA, Dodson EJ, (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-55.
41. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-21.
42. Krissinel E, Henrick K, (2004) Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr 60: 2256-68.
43. DeLano WL, (2008) DeLano Scientific LLC, CA, USA: Palo Alto. 1.2) Available at http://www.pymol.org (version.